Man Group PLC Allogene Therapeutics, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $157,092 - $241,150	-68,900 Reduced 83.31%	13,800 $44,000
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $436,214 - $820,137	-137,607 Reduced 62.46%	82,700 $262,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $997,990 - $1.48 Million	220,307 New	220,307 $1.09 Million
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $371,606 - $742,727	-48,576 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $52,467 - $97,981	-3,996 Reduced 7.6%	48,576 $725,000
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $1.1 Million - $1.45 Million	52,572 New	52,572 $1.35 Million
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $1.27 Million - $1.94 Million	-54,202 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $1.27 Million - $1.93 Million	-49,404 Reduced 47.68%	54,202 $1.91 Million
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $448,666 - $772,367	-17,776 Reduced 14.64%	103,606 $2.62 Million
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $221,317 - $307,301	6,835 Added 5.97%	121,382 $4.58 Million
Q2 2020 Aug 14, 2020	SELL	$18.39 - $54.04 $477,073 - $1.4 Million	-25,942 Reduced 18.47%	114,547 $4.91 Million
Q1 2020 May 15, 2020	BUY	$18.22 - $28.25 $1.63 Million - $2.53 Million	89,722 Added 176.73%	140,489 $2.73 Million
Q4 2019 Feb 18, 2020	BUY	$24.82 - $31.4 $1.26 Million - $1.59 Million	50,767 New	50,767 $1.32 Million
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $396,375 - $500,821	-15,181 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $475,901 - $578,864	-18,619 Reduced 55.09%	15,181 $408,000
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $838,916 - $1.1 Million	33,800 New	33,800 $977,000

Others Institutions Holding ALLO

# of Institutions

163

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account